Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Ratios

Immuneering (IMRX) Preferred Shares Issued (2020)

Immuneering has reported Preferred Shares Issued over the past 1 years, most recently at $37.2 million for Q4 2020.

Quarterly results put Preferred Shares Issued at $37.2 million for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2021 was $37.2 million (changed N/A YoY), and the annual figure for FY2021 was $24.8 million, down 33.36%.
Preferred Shares Issued for Q4 2020 was $37.2 million at Immuneering.
Over the last five years, Preferred Shares Issued for IMRX hit a ceiling of $37.2 million in Q4 2020 and a floor of $37.2 million in Q4 2020.